N'Deli L, Guelpa-Lauras C C, Perani E G, Grosset J H
Institut Raoul Follereau, Adzopé, Côte d'Ivoire, Paris, France.
Int J Lepr Other Mycobact Dis. 1990 Mar;58(1):12-8.
As a first clinical trial of a fluoroquinolone derivative in leprosy, ten previously untreated lepromatous leprosy patients, about two fifths of them with primary dapsone resistance but all susceptible to rifampin, were treated with pefloxacin 400 mg twice daily for 6 months. Definite clinical improvement was observed in all ten patients as early as 2 months after beginning treatment, and the morphological index was also drastically decreased to the baseline during the same period. The rapid bactericidal effects, as measured by serial mouse foot-pad inoculations, were demonstrated to the extent that about 99% of the bacilli were killed during the first 2 months of treatment. However, the bacterial load, in terms of the bacterial index and the number of acid-fast bacilli per mg of tissue, of the patients was only moderately reduced. The side effects were mild, and the patients tolerated the treatment well.
作为氟喹诺酮衍生物治疗麻风病的首次临床试验，10例未经治疗的瘤型麻风病患者，其中约五分之二对氨苯砜原发耐药，但对利福平均敏感，接受了每日两次400mg培氟沙星治疗，疗程6个月。早在开始治疗2个月后，所有10例患者均观察到明确的临床改善，同期形态学指数也急剧降至基线水平。通过连续小鼠足垫接种测量，显示出快速杀菌效果，在治疗的前2个月内约99%的杆菌被杀死。然而，患者的细菌载量，以细菌指数和每毫克组织中抗酸杆菌数量衡量，仅适度降低。副作用轻微，患者对治疗耐受性良好。
